Download PDF
Thromb Haemost 1995; 74(01): 364-368
DOI: 10.1055/s-0038-1642703
Symposium
Low Molecular Weight Heparin
Schattauer GmbH Stuttgart

Effectiveness and Safety of Low Molecular Weight Heparins (LMWH) in the Prevention of Venous Thromboembolism (VTE)

V V Kakkar
Thrombosis Research Institute, London, UK
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, West wick J. Low molecular weight heparin in the prophylaxis of venous thrombosis. Brit Med J 1982; 284: 375-379
    CrossrefPubMedGoogle Scholar
  • 2 Kakkar VV, Muraary WJ G. Efficacy and safety of low molecular weight heparin (CY216) in preventing postoperative venous thromboembolism:A cooperative study. Br J Surg 1986; 71: 788-791
    PubMedGoogle Scholar
  • 3 Hirsh J, Levine M. Low molecular weight heparin. Blood 1979; 1-17
    PubMedGoogle Scholar
  • 4 Fareed J, Walanga JM, Hoppensteadt D, Racanelli A, Coyne E. Chemical and biological heterogeneity in low molecular weight heparins: Implications for clinical use and standardization. Semin Thromb Hemost 1989; 15: 440-445
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Bendetowicz AV, Pacaud E, Beguin S, Uzan A, Hemker HG. On the relationship between molecular mass and anticoagulant activity of a low molecular weight heparin. Thromb Haemost 1992; 67: 556-562
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Béguin S, Wrelders S, Lormeau JC, Hemker HG. The mode of action of CY216 and CY222 in plasma. Thromb Haemost 1992; 67: 33-41
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucka JP, Berret E. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 1992; 340: 152-156
    CrossrefPubMedGoogle Scholar
  • 8 Leizorovicz A, Naugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparins in the prevention of perioperative thrombosis. Brit Med J 1992; 305: 913-920
    CrossrefPubMedGoogle Scholar
  • 9 Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Brit J Surg 1993; 30: 689-704
    PubMedGoogle Scholar
  • 10 Hull R, Raskob G, Pineo G, Rosenbloom D. et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. New Engl J Med 1993; 329: 1370-1376
    CrossrefPubMedGoogle Scholar
  • 11 Carter CJ, Kelton JG, Hirsh J, Cerskus AL, Santos AV, Gent M. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood 1982; 59: 1212-1237
    PubMedGoogle Scholar
  • 12 Esquivel CO, Bergqvist D, Bjoik CG, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polyphosphate on haemostasis and platelets in vivo. Thromb Res 1982; 28: 389
    CrossrefPubMedGoogle Scholar
  • 13 Prevention of Fatal Postoperative Pulmonary Embolism by Low Doses of Heparin: An International Multicentre Trial. Lancet 1975; 45-51
    PubMedGoogle Scholar
  • 14 Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3939-3980
    PubMedGoogle Scholar
  • 15 Petersen CB, Morgan WT, Blackburn MN. Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. J Biol chem 1987; 262: 7567-7575
    PubMedGoogle Scholar
  • 16 Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1717-1789
    PubMedGoogle Scholar
  • 17 Kakkar VV. Efficacy and safety of Clivarine and other LMWHs in general surgery: A meta-analysis. Blood Coag Fibrinol 1993; 4 Suppl (Suppl. 01) 23S-27S
    PubMedGoogle Scholar
  • 18 Kakkar VV, Cohen AT, Edmondson RA, Phillips MJ. et al. Low molecular weight heparin versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-265
    CrossrefPubMedGoogle Scholar
  • 19 Verstraete M. Pharmacokinetic aspects of unfracticmated and low molecular weight heparins. Dragsz 1990; 40 (04) 418-430
    PubMedGoogle Scholar
  • 20 Frydman A, Bara L, Laroux Y, Woler M, Chauliaa F, Duchier J, Samama M. The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin, in man given single subcutaneous doses of 20 up to 80mg. J Clin Pharmacol 1988; 28: 606-608
    PubMedGoogle Scholar
  • 21 Bradbrook ID, Magnani HM, Moelker HC, Morrison PJ, Robinson J, Rogers HS. et al. ORG10172 A low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Pharmacol 1987; 23: 666-667
    PubMedGoogle Scholar
  • 22 Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and Enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Brit J Surg 1994; 81: 1974-1976
    PubMedGoogle Scholar
  • 23 Brandt A, Bergemann R, Palmer A, Kirchoff B, Kakkar VV. Cost-effectiveness analysis oflow molecular weight heparin versus unfractionated heparin in orthopaedic and general surgery. 1995 Submitted for publication
    PubMedGoogle Scholar